Ectopic expression of Bcl-2 and Bcl-xL inhibits apoptosis induced by TNF-related apoptosis-inducing ligand (TRAIL) through suppression of caspases-8, 7, and 3 and BID cleavage in human acute myelogenous leukemia cell line HL-60

Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research
Betty Lamothe, Bharat B Aggarwal

Abstract

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is one of the latest members of the TNF superfamily known to induce apoptosis in a wide variety of tumor cells. Some cell types, however, are quite resistant to TRAIL. We investigated the effect of ectopic expression of Bcl-2 and Bcl-xL on TRAIL-induced apoptosis in human acute myelogenous leukemia HL-60 cells. We found that HL-60 cells, which express TRAIL receptors (also called death receptor, DR) DR4, DR5, and Dc (decoy) R2, are highly sensitive to TRAIL-induced cytotoxicity. Greater than 90% killing occurred within 24 h of TRAIL treatment. The expression of Bcl-2 and Bcl-xL, however, completely abolished the TRAIL-induced cytotoxic effects. Treatment of HL-60 cells with TRAIL induced caspase-8 activation within 2-4 h, but no activation could be seen in Bcl-2-expressing or Bcl-xL-expressing cells. TRAIL also induced cleavage of BID, which was also abolished by Bcl-2 and Bcl-xL. Similarly, TRAIL activated caspase-3 and caspase-7 in control cells but not in cells expressing Bcl-2 or Bcl-xL. Cleavage of the caspase-3 substrate poly(ADP-ribose) polymerase (PARP), was abrogated by ectopic expression of Bcl-2 and Bcl-xL. Inhibition of caspases by the pan-caspase...Continue Reading

References

Jul 19, 1994·Proceedings of the National Academy of Sciences of the United States of America·A R GottschalkJ Quintáns
May 31, 1996·The Journal of Biological Chemistry·R M PittiA Ashkenazi
Jun 1, 1996·Current Biology : CB·S A MarstersA Ashkenazi
Apr 4, 1997·Science·G PanV M Dixit
Oct 6, 1997·The EMBO Journal·H WalczakC T Rauch
Oct 7, 1997·The Journal of Experimental Medicine·M A Degli-EspostiC A Smith
Nov 5, 1997·The Journal of Biological Chemistry·M MacFarlaneE S Alnemri
Feb 21, 1998·Current Biology : CB·S A MarstersA Ashkenazi
May 2, 1998·The EMBO Journal·C ScaffidiM E Peter
Jun 11, 1998·The Journal of Biological Chemistry·J G EmeryP R Young
Aug 28, 1998·Science·N A Thornberry, Y Lazebnik
Oct 2, 1998·Advances in Immunology·A J MinnC B Thompson
Jan 20, 1999·The Journal of Experimental Medicine·S A SusinG Kroemer
Feb 4, 1999·Nature Medicine·L E French, J Tschopp
Feb 13, 1999·The Journal of Biological Chemistry·X M SunG M Cohen
Apr 21, 1999·Current Opinion in Cell Biology·A Ashkenazi, V M Dixit
Nov 5, 1999·Biochemical and Biophysical Research Communications·H YamadaS Kawanishi
Dec 1, 1999·Cell Death and Differentiation·N A Thornberry
Feb 7, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·X D ZhangP Hersey
Apr 27, 2000·Nature Cell Biology·J L BodmerJ Tschopp

❮ Previous
Next ❯

Citations

Jun 6, 2003·Cytokine & Growth Factor Reviews·Alexandru Almasan, Avi Ashkenazi
Mar 1, 2008·International Immunology·Isao NagaokaMichimasa Hirata
Apr 2, 2004·Reproduction : the Official Journal of the Society for the Study of Fertility·A KidsonM M Bevers
Mar 26, 2011·Apoptosis : an International Journal on Programmed Cell Death·Clarissa von HaefenKerstin Danker
Jul 8, 2014·International Journal of Molecular Sciences·You-Jin LeeSang-Youel Park
Jan 24, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Mamoun YounesAnas Younes
Oct 26, 2005·Leukemia Research·Karel SoucekAlois Kozubík
Jan 1, 2012·ISRN Microbiology·Isao NagaokaMichimasa Hirata
Mar 5, 2004·Biochimica Et Biophysica Acta·Martin R Sprick, Henning Walczak
May 3, 2014·International Immunopharmacology·Hui ShiXuejun Jin
Apr 27, 2017·Nanoscale·H BelkahlaO Micheau
May 23, 2007·Molecular and Cellular Biochemistry·Xiaojing YunJianxin Gu
Jan 18, 2003·World Journal of Gastroenterology : WJG·Li-Hua ChenBo-Quan Jin
Aug 8, 2006·Molecular Cancer Therapeutics·Jinrong ChengElizabeth A Repasky
Dec 30, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Frank A SinicropeXi Ming Tang
Jun 26, 2010·European Journal of Medicinal Chemistry·Débora C ReisHeloisa Beraldo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Apoptotic Caspases

Apoptotic caspases belong to the protease enzyme family and are known to play an essential role in inflammation and programmed cell death. Here is the latest research.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.